Navigation Links
Echo Therapeutics Expands Into New Headquarters in Philadelphia
Date:5/5/2011

PHILADELPHIA, May 5, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the relocation of its corporate headquarters from Franklin, MA to Philadelphia, PA.

The new office is located in the heart of Philadelphia's Center City Business District at 8 Penn Center.  Echo will continue to maintain and grow its Franklin office as its key operations hub where its engineering and product personnel are located.

"Since Echo Therapeutics' inception, the company has maintained its headquarters in Franklin where we have enjoyed a rewarding history of growth and success," stated Patrick Mooney, M.D., Echo's Chairman and CEO.  "The new headquarters responds directly to Echo's growing and evolving business and will accommodate both recent team expansion and additional hires planned for 2011 and beyond."

Echo operates at the following locations:

8 Penn Center, 1628 JFK Boulevard, Suite 300, Philadelphia, PA 19103 (Headquarters)

10 Forge Parkway, Franklin, MA 02038

About Echo TherapeuticsEcho Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals. For More Information:Patrick T. Mooney, M.D.

Media: Richard SternChairman and Chief Executive Officer

Stern &Co.(215) 717-4100

(212) 888-0044Connect With Us:- Visit our website at www.echotx.com

- Follow us on Twitter at www.twitter.com/echotx<
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
2. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
3. Amicus Therapeutics Announces First Quarter 2011 Financial Results and Continued Progress of Development Programs
4. Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
5. Cell Therapeutics to Re-submit Pixantrone NDA in Consideration for Accelerated Approval in Accordance with Guidance from FDAs Office of New Drugs
6. Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement With FTC Staff
7. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
8. Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6
9. United Therapeutics Corporation Reports First Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
11. Prime Therapeutics President and CEO Eric Elliott Delivers Speech at University of Minnesota College of Pharmacy Dialogues in Managed Care Leadership 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Inc. (NYSE MKT: CUR) announced that Jonathan D. ... long-term follow up data on the Phase I trial ... of amyotrophic lateral sclerosis (ALS or Lou Gehrig,s ... Symposium on ALS of the Foundation Andre-Delambre, in ... not open to the public, covered data up to ...
(Date:9/22/2014)... 22, 2014  AbbVie (NYSE: ABBV ... evaluating potential new medicines in the company,s oncology ... European Society of Medical Oncology (ESMO) Annual Congress, ... . Data being presented include results from a ... of veliparib (ABT-888), a poly (adenosine diphosphate [ADP]–ribose) ...
(Date:9/22/2014)... CAMBRIDGE, Mass. , Sept. 22, 2014  Seres ... diseases related to the human microbiome, today announced that ... one of 2014,s Fierce 15 biotechnology companies, designating it ... in the industry.  "Amid a great ... out for its focus and commitment to practical therapeutic ...
Breaking Medicine Technology:Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Seres Health Named a "Fierce 15" Biotech Company for 2014 2
... Barry Edison announces that Barry Edison Ophthalmology in ... Pelleve® Wrinkle Reduction System, a revolutionary skin-tightening system ... uses Pelleve—an advanced radiofrequency technology—because the treatment delivers ... results. "I am proud to now offer Pelleve ...
... 22, 2012  Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. ... Phase 3 trial evaluating Nexavar ® (sorafenib) tablets ... cell lung cancer (NSCLC) whose disease progressed after two ... endpoint of improving overall survival.  An improvement in the ...
Cached Medicine Technology:New Jersey Ophthamologist Now Offers Pelleve Wrinkle Reduction Treatment 2Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival 2Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival 3Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival 4Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival 5Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival 6
(Date:9/22/2014)... York, NY (PRWEB) September 22, 2014 ... pain on the side of the hip , which ... bursitis treatment in Manhattan. This treatment is now offered at ... which is also called trochanteric bursitis, occurs when the ... a fluid-filled sac in the hip, between the iliotibial ...
(Date:9/22/2014)... The concept of a whole eye transplant seems ... grant from the U.S. Department of Defense, researchers ... Medicine hope to someday make implantation of an ... eye transplant could be a holy grail for ... of ophthalmology and grant co-recipient with colleagues at ...
(Date:9/22/2014)... New York, US (PRWEB) September 22, 2014 ... Heartbeat Experts’ perspectives on stakeholder management needs for the ... speak with Heartbeat Experts on stakeholder strategies for any ... clinically meaningful points of differentiation within an increasingly crowded ... , The impact of identifying community-based thought ...
(Date:9/22/2014)... Va. (PRWEB) September 22, 2014 ... the nation’s leading nonprofit authority on the ... healthcare information exchange, announced findings from its recent ... Health Plan Identifier (HPID) within electronic transactions adopted ... (HIPAA). WEDI conducted the survey from August 20 ...
(Date:9/22/2014)... CareFlight Air & Mobile Services ... a new AS365 N3+ Dauphin, the latest version of ... which is based at Miami Valley Hospital ... air medical transport helicopters. , “We have a lot ... Health Vice President, Emergency, Trauma, and CareFlight. “We’ve been ...
Breaking Medicine News(10 mins):Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:Looking ahead: Whole eye transplant under development 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3
... MDAn original and progressive report on health information ... online today, makes ground-breaking recommendations for new ... tensions that currently mar relationships between many HIT ... indemnity and error management of HIT systems. In ...
... November 11, 2010 A new study from researchers in ... more likely to undergo a screening colonoscopy than those who ... for female endoscopists seem to be common among women. In ... notion that rates of screening colonoscopy can be increased by ...
... , THURSDAY, Nov. 11 (HealthDay News) -- U.S. ... to binge-drink, smoke cigarettes or use illicit drugs, a new ... likely to abuse prescription drugs, according to the Center ... from an analysis of 2002 to 2009 data from the ...
... in French . , Montreal, November 11, 2010 ... additional cardiac test when undergoing diagnosis for potential heart problems, ... du Qubec Montral and the Montreal Heart Institute. ... Journal of Cardiopulmonary Rehabilitation and Prevention , a large sample ...
... By Jenifer Goodwin HealthDay Reporter , ... synthetic marijuana known as "K2" is sending young people ... and hallucinations, toxicologists warn. In recent months, physicians ... up in emergency rooms after smoking synthetic marijuana. Despite ...
... chemist Dr Guillaume Lessene has been awarded the Walter and ... annual general meeting in Melbourne, Australia. The $AUD150,000 ... played in shaping the Walter and Eliza Hall Institute. It ... Burgh in August at the age of 94. ...
Cached Medicine News:Health News:Fortify HIT contracts with education and ethics to protect patient safety, say informatics experts 2Health News:Fortify HIT contracts with education and ethics to protect patient safety, say informatics experts 3Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 2Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 3Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 4Health News:Additional cardiac testing vital for patients with anxiety and depression 2Health News:'Fake Marijuana' Users Showing Up in Emergency Rooms 2Health News:'Fake Marijuana' Users Showing Up in Emergency Rooms 3Health News:Medicinal chemist wins inaugural De Burgh Fellowship 2
... For enzyme immunoassays, designed to meet the ... and allows the user to run set ... The floating manifold on this strip washer ... at a time. Reliable, compact, and self-contained, ...
... available to handle multiple assays: ... Embla 384 Cell washer has ... optimized to avoid cell disturbance. ... and have been integrated with ...
... miniGene LW is a new plate washing system ... and 384 channel microplates with flat, V-shaped or ... 8 or 16 channel nozzle heads. Simple LCD ... An optional plate stacker is available for the ...
Space-saving counter top model,User initiated manual defrost,Standard features (see above),Internal freezing compartment,Removable half-shelf in refrigerator,Two shelves in door,UL 471 Commercial Ref...
Medicine Products: